HIV medications - Revision history

Aidan: Added link for crushability chart

2024-01-25T12:32:51Z

Added link for crushability chart

← Older revision		Revision as of 12:32, 25 January 2024
Line 188:		Line 188:
	\|Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection.		\|Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection.
	\|}		\|}

			== Crushing Medications ==

			* See https://www.hivclinic.ca/main/drugs_extra_files/Crushing%20and%20Liquid%20ARV%20Formulations.pdf

	==Further Reading==		==Further Reading==

Aidan at 12:32, 4 January 2023

2023-01-04T12:32:30Z

← Older revision		Revision as of 12:32, 4 January 2023
Line 4:		Line 4:
	!Class		!Class
	!Examples		!Examples
			!Mechanism of Action
	!Description
			!Adverse Effects
	\|-		\|-
	\|Nucleoside reverse-transcriptase inhibitor (NRTI)		\|Nucleoside reverse-transcriptase inhibitor (NRTI)
	\|[[tenofovir]], [[emtricitabine]], [[abacavir]]		\|[[tenofovir]], [[emtricitabine]], [[abacavir]]
	\|Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.		\|Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.
			\|
	\|-		\|-
	\|Non-nucleoside reverse-transcriptase inhibitor (NNRTI)		\|Non-nucleoside reverse-transcriptase inhibitor (NNRTI)
	\|[[efavirenz]]		\|[[efavirenz]]
	\|Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.		\|Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.
			\|
	\|-		\|-
	\|Protease inhibitor (PI)		\|Protease inhibitor (PI)
	\|[[dirunavir]]		\|[[dirunavir]]
	\|Inhibits protease, which is required for processing proteins in the creation of the virion~~. Causes a metabolic syndrome~~.		\|Inhibits protease, which is required for processing proteins in the creation of the virion.
			\|Metabolic syndrome
	\|-		\|-
	\|Integrase strand transfer inhibitor (INSTI)		\|Integrase strand transfer inhibitor (INSTI)
	\|[[raltegravir]], [[dolutegravir]], [[bictegravir]]		\|[[raltegravir]], [[dolutegravir]], [[bictegravir]]
			\|
	\|Extremely potent with few side effects. Take separate from PPIs etc.
			\|Generally very well-tolerated; may cause weight gain and diabetes
	\|-		\|-
	\|Fusion inhibitor		\|Fusion inhibitor
			\|
	\|		\|
	\|		\|
Line 29:		Line 35:
	\|[[maraviroc]]		\|[[maraviroc]]
	\|Blocks entry of HIV into CD4 cells.		\|Blocks entry of HIV into CD4 cells.
			\|
	\|-		\|-
	\|CD4-mAb		\|CD4-mAb
	\|[[ibalizumab]]		\|[[ibalizumab]]
			\|
	\|		\|
	\|}		\|}

Aidan: /* Single-Tablet Regimens */

2020-08-18T01:14:31Z

Single-Tablet Regimens

← Older revision		Revision as of 01:14, 18 August 2020
Line 118:		Line 118:
	\|[[efavirenz]] (NNRTI)		\|[[efavirenz]] (NNRTI)
	\|No		\|No
	\|Older regimen. Neuropsychiatric symptoms, possibly including suicide.		\|Older regimen. Neuropsychiatric symptoms, possibly including suicide. No dose adjustment with [[rifampin]].
	\|-		\|-
	\|Biktarvy		\|Biktarvy

Aidan: /* Specific Medications */

2020-08-18T01:13:40Z

Specific Medications

Show changes

Aidan: /* Classes */

2020-07-28T14:18:08Z

Classes

← Older revision		Revision as of 14:18, 28 July 2020
Line 10:		Line 10:
	\| Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.		\| Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.
	\|-		\|-
			\| Non-nucleoside reverse-transcriptase inhibitor (NNRTI)
	\| Non-NRTI
	\| [[efavirenz]]		\| [[efavirenz]]
	\| Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.		\| Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.

Aidan: /* Considerations */

2020-07-28T14:17:17Z

Considerations

← Older revision		Revision as of 14:17, 28 July 2020
Line 174:		Line 174:
	\| Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection.		\| Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection.
	\|}		\|}

	== Considerations ==

	* [[Hepatitis B]]: Avoid [[Triumeq]]; use TDF/FTC-based regimen instead
	* CKD: Avoid [[Stribild]] in CrCl <70

	== Further Reading ==		== Further Reading ==

Aidan: /* Classes */

2020-07-28T14:16:29Z

Classes

← Older revision		Revision as of 14:16, 28 July 2020
Line 28:		Line 28:
	\| CCR5 entry inhibitor		\| CCR5 entry inhibitor
	\| [[maraviroc]]		\| [[maraviroc]]
		⚫	\| Blocks entry of HIV into CD4 cells.
⚫	\|
	\|-		\|-
	\| CD4-mAb		\| CD4-mAb
	\| [[ibalizumab]]		\| [[ibalizumab]]
		⚫	\|
⚫	\| Blocks entry of HIV into CD4 cells.
	\|}		\|}

Aidan: /* Considerations */

2020-06-11T14:24:56Z

Considerations

← Older revision		Revision as of 14:24, 11 June 2020
Line 177:		Line 177:
	== Considerations ==		== Considerations ==

	* Hepatitis B: Avoid Triumeq; use TDF/FTC-based regimen instead		* [[Hepatitis B]]: Avoid [[Triumeq]]; use TDF/FTC-based regimen instead
	* CKD: Avoid Stribild in CrCl <70		* CKD: Avoid [[Stribild]] in CrCl <70

	== Further Reading ==		== Further Reading ==

Aidan: /* Specific Medications */ added RTV

2020-02-16T02:05:25Z

Specific Medications: added RTV

← Older revision		Revision as of 02:05, 16 February 2020
Line 76:		Line 76:
	\| [[darunivir]] \|\| DRV \|\| PI		\| [[darunivir]] \|\| DRV \|\| PI
	\|		\|
			\|-
			\| [[ritonavir]] \|\| RTV \|\| PI
			\|
	\|-		\|-
	\| [[dolutegravir]] \|\| DTG \|\| INSTI		\| [[dolutegravir]] \|\| DTG \|\| INSTI

Aidan: /* Classes */ added Maraviroc

2020-02-16T01:51:37Z

Classes: added Maraviroc

← Older revision		Revision as of 01:51, 16 February 2020
Line 26:		Line 26:
	\|		\|
	\|-		\|-
	\| CCR5 inhibitor		\| CCR5 entry inhibitor
			\| [[maraviroc]]
	\|
	\|		\|
	\|-		\|-